final action
on 20 Nov 2024
Last Applicant/ Owned by
82152 Planegg
DE
Serial Number
79408855 filed on 26th Apr 2024
Registration Number
N/A
Correspondent Address
Filing Basis
1. filing basis filed as 66 a
Disclaimer
NO DATA
Research of pharmaceuticals; pharmaceutical drug development services; development of pharmaceutical preparations and medicines; research, development, and evaluation services in the fields of pharmaceuticals, medical therapies, immunology, vaccines, biotechnology, nanotechnology, gene therapy, lipids, lipid formulations, lipid nanoparticles, nucleic acids, including messenger rna, drug delivery a Read More
Preparation and dispensing of medications; fertility treatment; human fertility treatment services; vaccination services; regenerative medicine services; dispensing of pharmaceuticals; therapy services; medical treatment services; all of the aforementioned services not for the veterinary field.
N/A
N/A
Research of pharmaceuticals; pharmaceutical drug development services; development of pharmaceutical preparations and medicines; research, development, and evaluation services in the fields of pharmaceuticals, medical therapies, immunology, vaccines, biotechnology, nanotechnology, gene therapy, lipids, lipid formulations, lipid nanoparticles, nucleic acids, including messenger rna, drug delivery agents, nucleic acid therapeutics, and synthetic chemistry process technology; research and development of vaccines and medicines; vaccine research and development services; research and development services relating to vaccines; development of gene-based medicines; gene therapy research; research in the field of gene therapy; laboratory research in the field of gene expression; research in the field of gene editing technology; research and development services in the field of gene expression systems; advisory services relating to gene therapy research; biotechnology research; research and development in the pharmaceutical and biotechnology fields; biotechnology testing; scientific research relating to biology; scientific research in the field of genetics and genetic engineering; research relating to molecular sciences; information on the subject of scientific research in the field of biochemistry and biotechnology; scientific research in the field of genetics; scientific research relating to genetics; all aforementioned services not in the veterinary field.
N/A
N/A
Pharmaceuticals; pharmaceutical drugs; dermatological pharmaceutical products; pharmaceutical preparations; dermatological pharmaceutical substances; pharmaceutical compositions; anti-diabetic pharmaceuticals; cardiovascular pharmaceuticals; injectable pharmaceuticals; tissue-regenerative pharmaceutical preparations; cardiovascular pharmaceutical preparations; antibacterial pharmaceuticals; pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; inhaled pharmaceutical preparations for the treatment of respiratory diseases and disorders; anaesthetic preparations for inhalation; pharmaceutical preparations for inhalers; sanitary preparations and articles; hygienic preparations and articles; air deodorising and air purifying preparations; dental preparations; dental articles, namely materials for tooth restoration, dental cements, dental filing materials, bone fillers consisting of living materials as well as bone growth media consisting of biological materials for medical purposes; medicated dentifrices; dietary supplements and dietetic preparations; pest control preparations and articles; pharmaceutical preparations for the treatment of kidney diseases; respiratory stimulants; compounds for treating correlated pulmonary syndromes; medicines for the treatment of cardiovascular and cerebrovascular diseases; fertility enhancement preparations; pharmaceutical preparations for regulating the immune system; pharmaceutical preparations for the prevention of diseases of the immune system; pharmaceutical preparations for the prevention of disorders of the immune system; pharmaceutical preparations for the treatment of immune system related diseases and disorders; pharmaceutical preparations for the treatment of autoimmune diseases; pharmaceutical preparations for the prevention of autoimmune diseases; pharmaceutical preparations for the treatment of autoimmune disorders; pharmaceutical preparations for the prevention of autoimmune disorders; pharmaceuticals comprising nucleic acids; pharmaceuticals (MRNA) for the treatment of lung diseases; pharmaceuticals for the treatment of congenital diseases, in particular lung congenital diseases and/or autoimmune diseases; chemicals used for delivering nucleic acids to cells, in particular lipids for the delivery of nucleic acids; chemicals used for stabilizing nucleic acid delivery systems, in particular for stabilizing lipid nanoparticles; pharmaceutical preparations, such as, drug delivery agents in the nature of lipid nanoparticle carriers that facilitate delivery of pharmaceutical preparations and nucleic acid therapeutics; pharmaceutical preparations comprised of nucleic acids, including messenger rna, and lipid nanoparticles; pharmaceutical preparations comprised of lipid nanoparticles; autoantigens; vaccines; vaccine preparations; vaccine adjuvants; vaccines against pneumococcal infections; viral vaccines; human vaccine preparations; vaccines against flu; oral vaccine preparations; antiviral drugs for treating influenza; vaccines for human use; fat emulsions for medical infusions; medical preparations; medicinal healthcare preparations; medicinal infusions; medicinal preparations and substances; medicine; serotherapeutic medicines; antiallergic medicines; nucleic acid sequences for medical purposes; lipid nanoparticles for pharmaceutical, medical or diagnostic purposes; nanoparticle substances and nanoparticle preparations for medical and pharmaceutical purposes; nanoparticle materials for carrying and delivery of chemical, biochemical and pharmaceutical substances for vaccines; nanoparticle materials for carrying and delivery of chemical, biochemical and pharmaceutical substances for antibiotics; nanoparticle preparations for medicines, for stabilizing of chemical, biochemical, biological and pharmaceutical substances; acids for pharmaceutical purposes; adjuvants for medical purposes; cellular function activating agents for medical purposes; chemical preparations for medical purposes; nasal sprays for medical purposes; medicated nasal spray preparations; pharmaceutical preparations for the treatment of cancer; biological preparations for the treatment of cancer; biopharmaceuticals for the treatment of cancer; pharmaceutical products for the treatment of cancer; pharmaceutical preparations and substances for the treatment of cancer; pharmaceutical preparations and substances for the prevention of cancer; compounds for treating cancer; pharmaceutical preparations for activating cellular function; pharmaceutical preparations for the treatment of osteoporosis; pharmaceutical preparations for the treatment of hyperlipidemia; pharmaceutical preparations for the treatment of hypercholesteremia; pharmaceutical preparations for the prevention of osteoporosis; pharmaceutical preparations for the prevention of inflammatory diseases; pharmaceutical preparations for the prevention of allergies; pharmaceutical preparations for the prevention of diseases of the cardio-vascular system; pharmaceutical preparations for the prevention of diseases of the musculo-skeletal system; pharmaceutical preparations for the prevention of diseases of the respiratory system; pharmaceutical preparations for the prevention of inflammatory disorders; pharmaceutical preparations for the prevention of diseases of the genitourinary system; pharmaceutical preparations for the prevention of diabetes; pharmaceutical preparations for the prevention of diseases caused by bacteria; pharmaceutical preparations for treating arthritis; medicated ointments for treating dermatological conditions; medicated lotions for treating dermatological conditions; medicated creams for treating dermatological conditions; pharmaceutical preparations for treating gastrointestinal disorders; pharmaceutical preparations for treating chloasma; pharmaceutical preparations for treating diabetes; pharmaceutical preparations and substances; bronchodilating preparations; organotherapeutic preparations; chemico-pharmaceutical preparations; all of the aforementioned goods not for veterinary use.
N/A
N/A
Preservatives for pharmaceuticals; chemicals for use in industry and science; chemical substances for biological preparations regarding use in industry and science; biological preparations for use in industry and science; nucleic acids and organic chemicals for use in industry and science; industrial organic chemicals; organic chemicals for the industry; detergents for use in manufacture and industry; salts for industrial purposes; chemical and organic compositions for use in the manufacture of food and beverages; aqueous chemical compositions; triglycerides; nucleic recombinant acids; nucleic acids; nucleic acids for scientific purposes; pyrimidine; lipids for use in manufacture; lipids; lipid nanoparticles; lipid formulations for research purposes, or laboratory use; nanoparticle substances and nanoparticles for use in industry, science and research; nanoparticle substances and nanoparticle preparations for pharmaceutical research purposes; nanoparticle substances and nanoparticle preparations for scientific research in the field of medicine and pharmaceutics; hydrosoluble polymers; polymer dispersions; biodegradable polymer compositions; hydrogel polymer coatings; cationic polymers; polymer solutions; aqueous polymer dispersions; fatty acid esters; all of the aforementioned goods not for veterinary use.
N/A
N/A
No 79408855
No Service Mark
No
No
No
No
No
Yes
Yes
No
No
Status Date | Action Taken |
---|---|
07th Dec 2024 | REFUSAL PROCESSED BY IB |
20th Nov 2024 | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB |
20th Nov 2024 | REFUSAL PROCESSED BY MPU |
14th Nov 2024 | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW |
13th Nov 2024 | NON-FINAL ACTION WRITTEN |
12th Nov 2024 | ASSIGNED TO EXAMINER |
08th Nov 2024 | APPLICATION FILING RECEIPT MAILED |
08th Nov 2024 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
07th Nov 2024 | SN ASSIGNED FOR SECT 66A APPL FROM IB |